• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Eli Lilly booth at ASCO 2026
Biotech

ASCO: Lilly's faith in Kelonia rewarded with ‘nutty’ CAR-T data

Kelonia shared the largest slice of data yet for its in vivo CAR-T, helping to justify the $3.2 billion price tag Lilly recently paid for the biotech.
Darren Incorvaia May 31, 2026 8:00am
Eli Lilly Lilly

Lilly's $1.2B deal for Hanmi GLP-2 drug for short bowel syndrome

Jun 1, 2026 3:52am
Entry Japan with Clarity Execute with Confidence

PATH-Solution

Brought to you by Alfresa Holdings Corporation
ASCO
Favicon Fierce Pharma

Akeso's 34% overall survival win comes with caveats

May 31, 2026 8:00am
Revolution Medicines booth at ASCO 2026

ASCO: RevMed confident in RAS leadership as rivals square up

May 31, 2026 8:00am
Telix booth at ASCO 2026

ASCO: Telix tees up pivotal test for Pluvicto challenger

Jun 1, 2026 4:12pm
More News

At ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms

Jun 1, 2026 3:55pm

ASCO, Ryght AI team up for breast cancer trial site selection

Jun 1, 2026 2:00pm

Agios signs $165M deal for blood disorder drug that failed study

Jun 1, 2026 9:26am

Rallybio swerves past Candid pothole to land deal with Avenzo

Jun 1, 2026 9:09am
See more stories
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings